On December 11, 2025, Rhythm Pharmaceuticals announced preliminary results from its Phase 2 trial of setmelanotide for Prader-Willi syndrome, showing BMI reductions in some patients and safety consistent with prior profiles. The study enrolled 18 patients, with 6 of 8 achieving BMI reductions at Month 3 and 3 of 5 at Month 6.